Đang chuẩn bị liên kết để tải về tài liệu:
Study on prevalance of drug resistance and genetic mutation for drug resistance HIV on HIV/AIDS patients with first line antiretroviral treatment failure at Dongda hospital Ha Noi

Objectives: To study prevalence of drug resistance and genotype testing for drug resistance HIV on HIV/AIDS patients with first-line antiretroviral treatment failure at Dongda Hospital, Hanoi. Subjects and methods: Cross-sectional, descriptive, prospective study on 47 HIV/AIDS patients with first-line antiretroviral treatment failure at Dongda Hospital, Hanoi during period from 6 - 2011 to 12 - 2016. | Journal of military pharmaco-medicine n08-2017 STUDY ON PREVALANCE OF DRUG RESISTANCE AND GENETIC MUTATION FOR DRUG RESISTANCE HIV ON HIV/AIDS PATIENTS WITH FIRST-LINE ANTIRETROVIRAL TREATMENT FAILURE AT DONGDA HOSPITAL HA NOI Pham Ba Hien*; Do Tuan Anh**; Tran Viet Tien** SUMMARY Objectives: To study prevalence of drug resistance and genotype testing for drug resistance HIV on HIV/AIDS patients with first-line antiretroviral treatment failure at Dongda Hospital, Hanoi. Subjects and methods: Cross-sectional, descriptive, prospective study on 47 HIV/AIDS patients with first-line antiretroviral treatment failure at Dongda Hospital, Hanoi during period from 6 - 2011 to 12 - 2016. Results: The prevalence of drug resistance HIV was 90.7%; 97.7% resisted NNRTIs, following NRTIs: 95.3% and PIs group 11.6%. Among genetic mutations resistance to NNRTIs: G190A mutation was the highest (51.2%); K103N mutation was 39.5% and Y181C mutation was 34.9%. Genetic mutations in NRTIs: M184V mutation was 88.4%; in TAM mutations, K70R mutation was the most common (37.2%); followed D67N, T215F, T69N mutation was 27.9%; 27.9% and 25.6%, respectively. Genetic mutations in PIs: M36I and K20R mutation made up 9.3%. In NNRTIs, the prevalence of NVP resistance was 95.3% and ETR resitance was 4.7%. In NRTIs, lamivudine resistance was 93.0% and AZT resistance was 9.3%. No LVP/r resistance was recorded. Conclusions: Patients with first-line antiretroviral treatment failure had high prevalence of NNRTIs and NRTIs resistance but still susceptible to PIs. * Keywords: HIV; Drug resistance; First-line antiretroviral treatment failure; Genetic mutation for drug resistance. INTRODUCTION Thanks to antiretroviral (ARV) drugs that inhibit the growth of HIV, patients treated with ARV can live long and have reasonably heathy lives. ARV therapy is recommended due to the capacity assist the immune function and reduces HIVrelated adverse outcomes. ARV therapy widely used in patients with .